The precise lineage between neural stem cells and mature astrocytes remains poorly defined. To examine astrocyte development, we have characterized glial precursors from neural tissue derived from early embryonic ages. We show that CD44 identifies an astrocyte-restricted precursor cell (ARP) that is committed to generating astrocytes in vitro and in vivo in both rodent and human tissue. CD44+ cells arise later in development than neuronal-restricted precursors (NRPs) or tripotential glial-restricted precursors (GRPs). ARPs are distinguished from GRP and NRP cells by their antigenic profile and differentiation ability. ARPs can be generated from GRP cells in mass or clonal cultures and in vivo after transplantation, suggesting a sequential differentiation of neuroepithelial stem cells (NEPs) to GRPs to ARPs and then to astrocytes. The properties of ARPs are different from other astrocyte precursors described previously in their expression of CD44 and S-100h and absence of other lineage markers. Using a CD44 misexpression transgenic mouse model (CNP-CD44 mouse), we show that CD44 overexpression in vivo and in vitro decreases the number of mature glia and increases the number of O4+/GFAP+ cells tenfold. Misexpression of CD44 in culture inhibits oligodendrocytes and arrests cells at the precursor state. In summary, our data provide strong evidence for the existence of a CD44+ ARP in the developing nervous system. Published by Elsevier Inc.
Introduction
Development in the nervous system involves the sequential production of specific neural cells. The early born neural tube cells do not express markers characteristic of neurons, astrocytes, and oligodendrocytes but are multipotent and capable of generating differentiated neurons and glial cells in vitro and in vivo (Pevny and Rao, 2003; . These early born stem cells, however, do not differentiate into fully mature cells directly; rather, they generate more restricted proximate progenitors (blast cells) that undergo limited proliferation before maturing into fully differentiated cells. Many such proximate progenitors have been identified. These include neuronal precursors (Gage et al., 1995; Mayer-Proschel et al., 1997; Rao, 1999; Ray and Gage, 1994; Yang et al., 2000) , oligodendrocyte precursors (Liu and Rao, 2003a; Liu and Rao, 2004; Lu et al., 2002; Raff et al., 1983; Rowitch et al., 2002; Zhou and Anderson, 2002) , and astrocyte precursors (Alfei et al., 1999; Mi and Barres, 1999; Seidman et al., 1997) . Intermediate precursors such as neuronal-restricted precursors (NRPs) and glialrestricted precursors (GRPs) have been characterized in detail, and a lineage relationship between earlier multipotent precursor cells and more restricted progenitor cells has been established by clonal analysis, retroviral labeling, and transplant experiments (Han et al., , 2004 MayerProschel et al., 1997; Rao et al., 1998) .
The development of astrocytes remains less clear. Astrocytes may be derived from maturing radial glia (Voigt, 1989) or from distinct astrocyte precursors, whose existence in the brain has been inferred by retroviral lineage studies, which identify astrocyte-only clones in vivo Goldman, 1993, 1997) and the isolation of potential astrocyte precursor cells from the optic nerve (Barres et al., 1996) . It is also possible that multiple lineages for astrocytes may exist, which would be consistent with the existence of multiple classes of astrocytes (Miller et al., 1994) , whose distribution and temporal development cannot be readily explained by a single lineal path (Rajan and McKay, 1998) .
The ability to distinguish between these possibilities has been hampered by the lack of available markers that can be used to separate early precursor populations in vitro and in vivo. More recent experiments identify CD44, a transmembrane glycoprotein implicated in cell-matrix adhesion and matrix-mediated cell signaling (for review, see Naor et al., 1997) , as an early marker of astrocyte differentiation (Alfei et al., 1999; Moretto et al., 1993; Vogel et al., 1992) .
To understand the lineage relationship between bipotential glial and unipotential astrocyte precursors, we have utilized antibodies against CD44 to identify and isolate CD44-positive cells. We show that CD44+ cells are astrocyte-restricted precursors (ARP) present in the developing rodent spinal cord before the acquisition of GFAP immunoreactivity. CD44+ cells can be generated from GRPs and can be distinguished from GRP cells by antigen expression, cytokine dependence, and differentiation ability. Additionally, using a CD44 misexpression transgenic mouse model, we show that CD44 biases GRPs toward an astrocytic fate. Combined, our data provide strong evidence for the existence of a CD44+ ARP in the developing nervous system.
Materials and methods

Animals
Animal experiments were performed according to an approved ACUC animal protocol. C57BL/6 mice were purchased from NCI. Fisher 344 and timed pregnant Sprague-Dawley rats were purchased from Harlan (Indianapolis, IN). Human placental alkaline phosphatase (AP) transgenic Fisher 344 rats were generated and maintained as described (Kisseberth et al., 1999; Mujtaba et al., 2002) . CNP-CD44 transgenic mice were generated as previously described (Tuohy et al., 2004) . Briefly, mouse CD44 cDNA was cloned under the control of the mouse 2V ,3V -cyclic nucleotide-3V -phosphodiesterase (CNP) promoter, which was then linearized and used to generate founders. Founders were identified by Southern blot analysis of tail DNA using standard procedures.
Gene detection by RT-PCR
To analyze CD44 mRNA expression levels, reverse transcription-polymerase chain reaction (RT-PCR) was performed using RNA isolated from P1 wild-type rat spinal cord using the forward primer: 5V -CAG ACC TGC CCA ATG CCT TTG ATG GAC C-3V and the reverse primer: 5V -CAA AGC CAA GGC CAA GAG GGA TGC C-3V . GAPDH was used as an internal control. PCR was performed with the following conditions: 948C, 1 min; 628C, 1 min; and 728C, 2.5 min, for 30 cycles. The product is about 950 bp. The primers for amplification of CNP is 5V -CTT ACA AGATCATCC CTG-3V and 5V -AAG TAG AGT GGC AGA AAG T-3V . The product is 312 bp.
Cultures of neural precursor cells
Rodent neural precursor cells were isolated as described previously (Kalyani et al., 1998; Mayer-Proschel et al., 1997) . Briefly, E14.5 time-pregnant Sprague-Dawley neural tubes were isolated and incubated in 0.05% Trypsin EDTA (Invitrogen) at 378C for 10 min. Excess trypsin were removed and tissue fragments were triturated in NEP basal medium (NEP, Kalyani et al., 1998) to obtain a suspension of single cells. Cells were grown in NEP basal medium supplemented with basic fibroblast growth factor (bFGF, 20 ng/ml, Peprotech, Rocky Hill, NJ). To induce oligodendrocyte differentiation, human platelet derived growth factor BB (PDGF BB, 10 ng/ml, Upstate Biotechnology, Lake Placid, NY) and 3,3,5 triiodothyronine (T3, 30 ng/ml, Sigma, St. Louis, MO) were added. To promote astrocyte differentiation, 10% fetal calf serum (Sigma) was added. To induce neuronal differentiation, retinoic acid (RA, 17.5 ng/ ml; Sigma) and neurotrophin 3 (NT 3, 10 ng/ml; Peprotech) were added.
Human neural precursor cells were purchased from ScienCell Research Laboratories (San Diego, CA). Experiments involving human cells were performed in accordance with principles embodied in the Declaration of Helsinki (Code of Ethics of the World Medical Association). Cells were maintained in human neural precursor cell medium (ScienCell Research Laboratories) supplemented by 1% fetal bovine serum. After 20 days in culture, almost all cells became CD44+ and did not express neuronal or glial cell markers. These cells were used for transplantation into adult rat spinal cord (see below).
Cell sorting by flow cytometry
Purification of A2B5+ GRP cells was performed as described (Cai et al., 2002) . Briefly, to isolate A2B5+ GRPs, E14.5 spinal cords from wild-type timed pregnant SpragueDawley rats (for mass culture and clonal analysis) or timed-pregnant AP transgenic rats (for transplantation experiments) were acutely dissociated and incubated with A2B5 antibodies (1:20, ATCC hybridoma supernatant) at 48C for 1 h. The unbound antibodies were washed out and the cells incubated in FITC-conjugated antimouse IgM secondary antibody (1:200, Jackson ImmunoResearch, West Grove, PA) for 30 min. After washing, the cells were resuspended in 5% FBS in 1Â PBS at a density of 0.5 Â 10 7 to 1 Â 10 7 per milliliter. Cell purification was performed with a FACSstar Plus cell sorter (Becton Dickinson Immunocytometry Systems, San Jose, CA) at 48C at a rate of 2500 cells/ s. The cells were collected at 48C and A2B5+ sorted cells were checked by immunostaining and found to have a purity of 90-99%.
To isolate CD44+ cells, dissociated E14.5 spinal cord cells were plated on poly-l-lysine and laminin-coated dishes and cultured in NEP basal medium in the presence of 20 ng/ml bFGF for 24 h, then cells were grown for 3 days in NEP basal medium supplemented with bFGF (20 ng/ml) and bone morphogenetic protein 2 (BMP-2, 20 ng/ml, R&D Systems, Minneapolis, MN). Medium was changed every other day. The cells were dissociated by trypsin digestion and were then incubated with CD44 antibodies (2.5 Ag/ml, Chemicon, Temecula, CA) at 48C for 1 h. The unbound antibodies were washed out. The cells were incubated in Alexa-488 antimouse IgG secondary antibody (1:500, Molecular Probes, Eugene, OR) for 30 min. Then CD44+ cells were sorted using a method similar to that described above for A2B5+ cells. CD44+ sorted cells were checked by immunostaining and found to have a purity of N95%. Purified A2B5+ or CD44+ cells were plated in NEP basal medium for mass culture, clonal analysis, and transplantation.
Clonal cultures of neural precursor cell
Flow-cytometry-purified cells or unsorted control cells were plated at 1 cell/well in 96-well plates, maintained in NEP supplemented with bFGF (20 ng/ml) for 7 days, and then bFGF was withdrawn and differentiating factors (RA, 17.5 ng/ml; NT-3, 10 ng/ml; PDGF-BB, 10 ng/ml; T3, 30 ng/ml) were added. The cells were cultured for an additional 10-14 days before processed for immunocytochemistry as described below. In general, about 50% of single cells survive the cloning process, which is similar to other cells subjected to clonal analysis .
Intraspinal grafting into the adult intact spinal cord Transplantation was performed as described before (Han et al., 2004) . Briefly, flow cytometry purified rat A2B5+ or CD44+ cells or human CD44+ cells maintained in culture were dissociated and resuspended in fresh culture media at a concentration of 25,000 cells/Al. Adult female Sprague-Dawley rats were anesthetized and a single dose of cells was microinjected into the cervical spinal cord. Animals received Buprenex and were immunosuppressed with Cyclosporin A (Sandoz Pharmaceuticals, East Hanover, NJ).
Posttransplantation analysis
Animals were sacrificed at 2 and 4 weeks, perfused with 4% paraformaldehyde, and cryoprotected in 30% sucrose-0.1 M phosphate buffer at 48C for 3 days (Han et al., 2004) . Spinal cord fragments centered at the injection site were identified and embedded in O.C.T. (Fisher Scientific). Blocks were processed for AP histochemistry and immunohistochemistry analysis.
Immunohistochemistry and immunocytochemistry
Spinal cord and brain tissues were dissected and fixed with 4% paraformaldehyde, cryoprotected with 30% sucrose, and embedded in O.C.T. as described . Cultured cells were isolated and processed for immunocytochemistry as described previously (MayerProschel et al., 1997) . BrdU incorporation assay was performed as described (Cai et al., 2002 
Western blotting
Whole brains were minced on ice, homogenized, and lysed in ice cold 50 mM Tris-HCl pH 7.4 containing 150 mM NaCl, 0.5% Nonidet P-40, 1 mM phenyl-methylsulfonyl fluoride, and 10 Ag/ml leupeptin. Lysates were then analyzed by SDS-polyacrylamide gel electrophoresis and Western blotting as previously described (Sherman et al., 2000) . Anti-GFAP was used at 1:500 (DAKO).
Flow cytometry to quantify double-positive cells
Whole brains were dissected and dissociated into single cells as described (Tuohy et al., 2004) . To quantify double-positive cells, dissociated cells were incubated with GalC or O4 and GFAP primary and appropriate secondary antibodies as previously described (Sherman et al., 1995) , then z10,000 cells were counted for fluorescence in all three channels using a FACS Calibur cytometer (BD Biosciences).
Results
Expression of CD44 is restricted to the astrocyte lineage in vivo and in vitro
CD44 is expressed early (E10) during chicken embryonic spinal cord development and appears to identify astrocyte precursor cells (Alfei et al., 1999) . To determine whether CD44 could be used to identify an astrocyte precursor population in rodents, we examined its expression by immunocytochemistry using developing mouse and rat neural tubes from E10.5 onward (Figs. 1A-E). Expression was seen as early as E11.5 in rat and E15.5 in mouse (Fig. 1B) well before the expression of GFAP . Among all the splice variants of CD44, only the standard form of CD44 (CD44s) was detected by RT-PCR (Fig. 1F , lane 4 and data not shown).
In mice, CD44 expression was first seen in the dorsal horn and dorsal gray matter, with a more ventral distribution later in development (Fig. 1C) . At this stage, CD44 expression did not colocalize with markers specific to the neuronal lineage, such as h-III tubulin, E-NCAM and NeuN, or oligodendroglial lineage, such as PDGFRa, NG2, Sox10, GalC, O4, MBP and data not shown). By P1, many cells in the ventral white matter coexpressed CD44 and GFAP, the mature astrocyte marker (Figs. 1C-E; Liu et al., 2002) . Even at this stage, CD44+ cells did not colabel with markers of either neuronal or oligodendrocyte lineage , summarized in Fig. 1I ), suggesting that CD44 is expressed in the astrocyte lineage and its expression precedes the GFAP expression.
To assess the differentiation potential of CD44-expressing cells more directly, we purified CD44+ cells by flow cytometry sorting (see Materials and methods) and examined their ability to differentiate in mass and clonal cultures. Sorted CD44+ cells from E14.5 rat spinal cord plated in NEP basal medium supplemented with bFGF (20 ng/ml) divided and proliferated in culture as shown by their ability to incorporate BrdU (Fig. 1H ). Double labeling of undifferentiated CD44+ cells showed that these cells expressed some astrocytic markers but did not express markers characteristic of the neuronal or oligodendroglial lineages (Fig. 1I ). CD44+ cells could be maintained in an undifferentiated state over multiple passages in NEP basal medium in the presence of bFGF (20 ng/ml). When induced to differentiate in media that promote neuronal differentiation (NEP with 17.5 ng/ml RA and 10 ng/ml NT-3), or oligodendrocyte differentiation (NEP with 10 ng/ml PDGF-BB and 30 ng/ml T3), or astrocyte differentiation (NEP with 10% fetal calf serum), CD44+ cells, unlike stem cells or GRP cells, differentiated almost exclusively into astrocytes as assessed by GFAP expression (Figs. 1J-L) under any of the above conditions. No neuronal or oligodendrocyte differentiation was seen. In contrast, unsorted cells were able to generate neurons, oligodendrocytes, and astrocytes ( Fig. 1G ) under identical culture conditions. Previous reports also showed that NRPs differentiated into neurons and GRPs into oligodendrocytes and astrocytes, respectively, in these conditions (Mayer-Proschel et al., 1997; Rao et al., 1998 ; data not shown). Thus, CD44+ cells are a dividing population that is biased in its differentiation potential to generate astrocytes but not oligodendrocytes or neurons in culture in vitro.
To further confirm the differentiation potential of CD44+ cells, we repeated clonal analysis in three independent experiments using sorted CD44+ cells (purity N 95%). CD44+ sorted cells were plated at 1 cell/well in 96-well plates, propagated in NEP supplemented with bFGF (20 ng/ ml) for 7 days, allowed to differentiate in differentiating medium containing RA (17.5 ng/ml), NT-3(10 ng/ml), PDGF-BB (10 ng/ml), and T3 (30 ng/ml) for an additional 10-14 days before they were processed for immunocytochemistry analysis.
All 107 clones tracked showed differentiation into GFAP+ astrocytes and greater than 90% differentiated solely into astrocytes. Only 2/107 (1.87%) contained an occasional h-III tubulin immunoreactive cell, and 6/107 (5.61%) of them a few GalC immunoreactive cells. In contrast, when we analyzed the clones obtained from unsorted cells, significantly more clones are positive for h-III tubulin (16/53, 30.19%) or GalC (10/53, 18.87%). Thus, in both mass and clonal culture, the differentiation potential of CD44+ cells isolated from rat developing spinal cord is biased to an astrocyte lineage in vitro.
CD44-expressing cells generate astrocytes but not oligodendrocytes or neurons in vivo
To determine whether the in vitro results predicted the behavior of CD44+ cells in vivo, we examined the ability of CD44+ cells to differentiate after transplantation into the adult rat spinal cord. The spinal cord was selected because we have previously shown that two other lineage-restricted precursors, NRP cells and GRP cells, were able to survive, proliferate, and differentiate into predicted cells types in the adult spinal cord environment after transplantation (Han et al., , 2004 . To follow transplanted cells in vivo, we prepared CD44+ cells from E14.5 AP transgenic rats (Kisseberth et al., 1999) . These cells, marked by AP expression, can be easily and permanently distinguished from the wild-type host cells by AP histology or immunohistochemistry (Kisseberth et al., 1999; Mujtaba et al., 2002) . Sorted CD44+ cells from E14.5 AP rat embryos were then grafted into adult rat spinal cord (n = 8 per time point, total n = 16) and their differentiation assessed. Two and 4 weeks posttransplantation, sagittal sections (average 50 sections per rat, with 10-12 sections containing transplanted cells per animal of a 10-mm-long spinal cord fragment) were collected for immunocyto- Fig. 1 . CD44 is expressed in mouse and rat cells of astrocyte lineage. CD44 expression could not be detected until E15.5 in mouse dorsal spinal cord (A, B) and the first appearance of CD44-positive expression was detected in the dorsal gray matter (B). At P1, CD44+ cells could be found in ventral cord and coexpressed the astrocyte marker GFAP (C-E). Sorted CD44+ cells dissociated from E14.5 rat spinal cord were able to incorporate BrdU (H) and did not coexpress oligodendrocyte markers Olig2, Nkx2.2, and GalC or neuronal marker h-III tubulin (I), but they differentiated into GFAP+ astrocytes in culture (J-L), while unsorted cells from E14.5 rat spinal cord (G) gave rise to cells of neuronal (h-III tubulin, green), oligodendrocytic (GalC, red), and astrocytic (GFAP, blue) lineages. Because CD44 is a cell membrane protein and GFAP is a cytoplasmic protein, double-labeled cells did not necessarily show yellow staining in the picture. An example of a cell coexpressing CD44 and GFAP was designated by arrow and high-magnification pictures were shown in K and L. RT-PCR further showed that the CD44 molecule that was expressed in rodent spinal cords was the standard form of CD44 (F), lane 1, plasmid DNA; lane 2, control without RNA; lane 3, control without Taq; lane 4, P1 rat spinal cord cDNA. Scale bar, A-E, 200 Am; G, H, J-L, 100 Am.
chemistry. Transplanted cells were identified by AP immunostaining. Two weeks posttransplantation, coexpression of AP with CD44+ and S-100h were readily detected, and occasional AP+ donor cells had begun to express GFAP (data not shown). However, at 4 weeks posttransplantation, many more GFAP+/AP+ cells were seen (Figs. 2A-CU and data not shown), indicating these grafted cells have progressed toward maturation along the astrocyte lineage. In contrast, no transplanted cells (eight animals, four to six sections each) appeared to have differentiated into neurons or oligodendrocytes (Figs. 2D-IU) . To confirm the double labeling of astrocyte markers with AP, the donor cell marker, we used confocal microscopy to reconstruct overlap of the two markers in double-labeled cells (Fig. 2) . Astrocytes have small cell bodies and large number of processes making it difficult to quantify exact numbers of double-positive cells. However, all animals (n = 16) grafted showed differentiation into astrocytes and none showed differentiation into neurons or oligodendrocytes. Thus, as in vitro, CD44+ cells from AP transgenic rats are biased to the astrocyte lineage after transplantation.
CD44+ astrocyte precursors are derived from A2B5+ GRP cells in vitro
We have previously shown that A2B5-immunoreactive GRP cells differentiate into oligodendrocytes and astrocytes Wu et al., 2002) , both in vitro and in vivo. Our present results raised the possibility that A2B5+ GRP cells may be the lineal ancestor of CD44+ astrocyte precursors. To test this hypothesis, we purified A2B5 immunoreactive cells by flow cytometry sorting as described previously (Cai et al., 2003; Wu et al., 2003) and examined the ability of these A2B5+ cells to differentiate into CD44+ cells. Sorted A2B5+ cells did not express PSA-NCAM or radial glial markers (data not shown). After sorting, the A2B5+ cells were plated in Fig. 3 . A2B5+ GRP cells generate CD44+ cells in both mass and clonal culture. E14.5 rat spinal cord cells were dissociated and sorted to isolate A2B5+ cells. Eight hours after plating, greater than 99% of the cells in culture were A2B5 immunoreactive (A) and no cells coexpressed CD44 (B). By 5 days of culture, a majority of the cells had obtained CD44 immunoreactivity (D-F) ; by 7 days of culture, CD44+ cells differentiated into GFAP+ astrocytes (G-I). Clonal analysis was also performed using A2B5+ sorted cells. Top row shows phase contrast images, the middle row shows A2B5 immunostaining of live colonies, and the bottom row CD44 immunostaining. By comparing A2B5 and CD44 staining, one can see that during the 3 days in culture, cells expanded from a single A2B5+ cell (AV , DV , GV , JV , and MV ), gradually lost A2B5 immunoreactivity (BV , EV , HV , KV , and NV ), and acquired CD44 expression (CV , FV , IV , LV , and OV ). Scale bar in A-I, 100 Am; AV -OV , 50 Am.
NEP + bFGF (20 ng/ml). After 8 h in culture, more than 99% of the cells were A2B5 immunoreactive and these cells did not express detectable levels of CD44 (Figs. 3A-C). These cells were maintained in NEP basal medium supplemented with bFGF (20 ng/ml) and BMP-2 (20 ng/ml), most A2B5+ cells differentiated into CD44 expressing cells by day 5, of which a small percentage colabeled for A2B5 and CD44, indicating the existence of the transition state (Figs. 3D-F) . After 7 days in vitro, virtually all cells became GFAP+ astrocytes (Figs. 3G-I) , and many cells were GFAP+/CD44+. No transitional A2B5+/CD44+ cells could be detected at this time. Our clonal culture results (total 50 clones) further confirmed the mass culture data. An example of a clone we followed is shown in Figs. 3AV -OV . Single A2B5+ cells proliferated to form a colony, and in differentiation conditions gradually lost A2B5 immunoreactivity and acquired CD44 expression (Figs. 3AV -OV ). As in mass culture, cells passed through a stage where they coexpressed A2B5 and CD44 (compare Figs. 3KV ,LV ) before they became CD44+/A2B5- (Figs. 3NV ,OV ) . To exclude the possibility that A2B5+ cells may include some neuronal cells, we repeated the experiments using double selection to obtain A2B5 immunoreactive and E-NCAM negative cells. Results obtained confirmed that A2B5+ glial precursors generate CD44+ astrocyte precursors that subsequently mature to acquire GFAP immunoreactivity.
The transition from A2B5+ to CD44+ to GFAP+ is regulated by BMP and leukemia inhibitory factor (LIF)
To elucidate the factors that are important in the transition from A2B5+ GRP cells to CD44+ astrocyte restricted precursors and then GFAP+ astrocytes, we tested the potential of two growth factors, BMP and LIF, which have been shown to promote astrocyte differentiation (Mehler et al., 1997; Richards et al., 1996) . A2B5+ GRP cells were harvested as described previously and maintained in NEP in the presence of 20 ng/ml bFGF for 24 h after sorting and then treated differently: in FGF group (lanes 1 and 2 in Fig. 4 ), cells were grown in NEP/bFGF alone (2 ng/ml, to decrease self-renewal but sufficient for cell survival); in BMP group (lanes 3 and 4 in Fig. 4 ), cells were grown in NEP, bFGF (2 ng/ml), and BMP-2 (20 ng/ml); in LIF group (lanes 5 and 6 in Fig. 4) , LIF (20 ng/ml, R&D systems) were added in the place of BMP; and in BMP+LIF group (lanes 7 and 8 in Fig. 4) , both BMP (20 ng/ml) and LIF (20 ng/ml) were added to NEP/bFGF (2 ng/ml). GFAP and CD44 expressions were examined by immunohistochemistry after 3 days, the cells expressing CD44 or GFAP were counted and the numbers analyzed for significance by Student's t tests. Treatment with BMP alone promoted the acquisition of CD44 immunoreactivity as indicated by the increased numbers of CD44+ cells (Fig. 4, lanes 1 and 3, P b 0.05) . However, no significant up-regulation of the number of GFAP-expressing cells was seen (Fig. 4 , lanes 2 and 4, P N 0.05; also lanes 3 and 4, P b 0.05). Treatment with LIF alone promoted both CD44 and GFAP expression, but the increased number of CD44-expressing cells was not as dramatic as in cells treated with BMP (Fig. 4, lanes 5 and 6) . In contrast, BMP and LIF in combination significantly elevated the number of both CD44+ and GFAP+ (Fig.  4 , lanes 1 and 7, P b 0.001; lanes 2 and 8, P b 0.05). Thus, BMP and LIF both promote astrocyte differentiation and their effects are synergistic with BMP causing a down-regulation of the number of A2B5 immunoreactive cells and an increase of the number of CD44+ cells, with LIF mainly promoting the number of GFAP-expressing cells. The statistic results are based on five independent experiments. These data are consistent with previous reports that suggest that, in telencephalic neural stem cells, BMP alone only induces astrocyte differentiation to a certain intermediate stage and additional signal(s) is needed for further maturation (Nakashima et al., 2001 ).
A2B5+ GRP cells generate CD44+ astrocyte precursors in vivo
Our previous results have shown that A2B5+ GRP cells, unlike oligodendrocyte type-2 astrocyte precursors (O-2As), generate astrocytes in vivo ) and our present results suggest that they do so by first generating a CD44+ Fig. 4 . BMP and LIF promote differentiation of A2B5+ cells. A2B5+ sorted cells were treated with bFGF (2 ng/ml, lanes 1 and 2); BMP-2 (20 ng/ml) and bFGF (2 ng/ml, lanes 3 and 4); LIF (20 ng/ml) and bFGF (2 ng/ml, lanes 5 and 6); BMP-2 (20 ng/ml), LIF (20 ng/ml) and bFGF (2 ng/ ml, lanes 7 and 8) respectively. By the end of the 3-day treatment, BMP has significantly promoted the acquisition of CD44 expression (lane 1 and 3, P b 0.05). Treatment with LIF alone also promoted the acquisition of CD44 expression but not as dramatically as BMP treatment (lanes 1 and 5). BMP treatment alone did not induce the acquisition of GFAP significantly (lanes 2 and 4, P N 0.05), while a combination of BMP and LIF treatment promoted acquisition of both CD44 and GFAP expression (lanes 1 and 7, P b 0.001; lanes 2 and 8, P b 0.05). The graph represents five independent experiments and the value represents mean F SE. Two-sample t tests were performed. precursor cell. To confirm that as in vitro, A2B5+ glial progenitor cells transit through a CD44+ stage, we transplanted A2B5+/CD44À GRP cells harvested from AP transgenic rats (Kisseberth et al., 1999; Mujtaba et al., 2002) into adult rat spinal cord (Fig. 5) . Animals (n = 8) were sacrificed at 2 weeks posttransplantation. Sagittal sections (averaged 10-12 sections per rat) of a 10-mm-long spinal cord segment, where A2B5+ cells were grafted, were collected to assess the phenotype of transplanted cells. Consistent with the in vitro data, these transplanted A2B5+ cells acquired CD44 and GFAP expression and differentiated into astrocytes (Figs. 5D-I) . As previously described and in contrast to our experiments with transplanted NRPs , no neuronal differentiation was seen (Figs. 5J-L) . Thus, signals exist to direct the differentiation of A2B5+ GRP cells into astrocytes in vivo and the differentiation involves the acquisition of CD44 immunoreactivity.
Misexpression of CD44 in glial progenitors alters differentiation of oligodendrocytes and astrocytes
To further evaluate the role of CD44 in the differentiation of astrocytes, we utilized the CNP-CD44 transgenic mouse model. In this model, CD44 is expressed under the control of the CNP promoter that drives CD44 expression in glial progenitors as early as E12.5 in mouse (Chandross et al., 1999; Tuohy et al., 2004) , and RT-PCR and immunocytochemistry showed that CNP is also expressed in both mouse and rat A2B5+ glial precursors (Fig. 7A ). Both heterozygous and homozygous mice show a twofold to fourfold increase in CD44 expression in the CNS at P1 (Tuohy et al., 2004) . This overexpression persists till adulthood and leads to a severe demyelination with an associated accumulation of oligodendrocyte precursors as assessed by expression of PDGFRa, Nkx2.2, Sox10, O4, and GalC (Figs. 6B and 7J,K; Tuohy et al., 2004) , suggesting that CD44 misexpression prevents further maturation of glial progenitors. Because CD44 expression signals a bias to the astrocyte lineage, we examined this mutant to assess whether the failure to mature into oligodendrocytes and accumulation of precursors was Fig. 6 . Increased number of astrocytes and accumulation of oligodendrocyte precursors in 1-month-old CNP-CD44 mice. Cells from 1-month-old CNP-CD44 transgenic and wild-type mouse spinal cords were dissociated and double labeled with GalC and GFAP (A). About 10-fold more cells coexpressed GalC and GFAP in heterozygous and homozygous mice than wild-type animals, as shown in the upper right quadrant of each flow cytometry graph. Immunohistochemistry shows that the number of PDGFRa+ oligodendrocyte precursors increased in both heterozygous and homozygous transgenic mice (B). The number of astrocytes, especially the gray matter astrocytes, also increased dramatically in transgenic animals as shown by GFAP staining (C). Scale bar, 200 Am.
associated with an increase in differentiation into astrocytes. One-month-old transgenic animals (before overt demyelination and any potential inflammatory response) were examined for GFAP expression and for the presence of double labeled GalC+/GFAP+ or O4+/GFAP+ cells. Consistent with our hypothesis, we observed a 10-fold increase in the coexpression of GalC and GFAP or O4 and GFAP in transgenic animals (Fig. 6A) . Also consistently noted was a twofold increase in numbers of GFAP-expressing cells by flow cytometry analysis (Figs. 7B and C, labeling intensity over background, wild type 33%, and CNP-CD44 mice 66%) and an increase in GFAP immunoreactivity particularly in the gray matter by immunostaining (Figs. 6C and  7E-H) .
To test the effect of CD44 misexpression more directly, we transfected CD44 (along with H2B-GFP, which drives GFP expression in the nucleus) into A2B5+/O4+/O1À/ MBPÀ cells, then challenged them to differentiate in the presence of ciliary neurotrophic factor (CNTF) and T3 to become oligodendrocytes. Nontransfected cells became O1 Fig. 7 . Overexpression of CD44 alters cell fate both in vitro and in vivo. A2B5+/O4+/O1À/MBPÀ cells isolated from mouse cortex were cotransfected with CD44 and H2B-GFP (which drives GFP expression in the nucleus), and were grown in the presence of CNTF and T3 to promote oligodendrocyte differentiation (I). Cells overexpressing CD44 (with green fluorescence in the nuclei and CD44 staining in the cytoplasm as designated by (arrowhead) did not express any mature oligodendrocyte markers, while nontransfected cells became O1 positive (green, arrow) and MBP positive (not shown). In order to confirm this in vivo, we used CNP-CD44 transgenic mice where the CNP promoter drives expression of CD44 in A2B5+ glial progenitors or later-appearing glial cells shown by RT-PCR in (A). Brains of 1-month-old homozygous CNP-CD44 transgenic mice and their wild-type littermates were processed for immunostaining and flow cytometry to assess the difference of the expression of MBP and astrocyte marker GFAP. E-H show the representative staining of GFAP in the rostral diencephalon; (E and G) are from the wild-type mouse brains of the areas indicated in (D); (F and H) are from the corresponding areas of the CNP-CD44 transgenic mouse brains. Both areas show elevated GFAP expression in transgenic samples. Statistical t test analysis of the fluorescence density of 10 such areas confirmed that twofold to threefold increases of GFAP expression were found in transgenics. Consistent with the immunostaining data, the flow cytometry analysis also showed twofold increase in GFAP expression (B and C). In contrast, demyelination as assessed by MBP staining was obvious in homozygous transgenic animals (J and K). Fig. 8 . Human CD44+ cells share similar properties with their rodent counterparts. CD44+ cells derived from commercially available human neural precursors were able to incorporate BrdU (A), expressed nestin (B), did not colabel with GRP cell marker A2B5 (C) and neuron marker h-III tubulin (F), but coexpressed astrocyte markers S-100h (D) and GFAP (E). After transplantation into adult rat spinal cord, human-derived CD44+ cells, as identified by human-specific nuclear antibody (hNUC) continued to divide as implicated by Ki-67 staining (AV -CV , green). When these cells differentiated, they expressed astrocyte markers such as GFAP (DV -FV ), but not markers of neuronal or oligodendrocytic lineage (not shown). Scale bar in A-F, 100 Am; AV , 500 Am, BV -CV , 50 Am.
positive (and MBP positive) and developed the morphologies of mature oligodendrocytes (Fig. 7I) , while cells overexpressing CD44 failed to mature confirming that the block in maturation seen in vivo is due to the direct effect of CD44 on glial progenitors (Fig. 7I) . Cells overexpressing CD44 did not spontaneously differentiate into astrocytes but required additional signals such as LIF (data not shown).
Overall, our data suggest that CD44 overexpression in glial progenitors inhibits their maturation to oligodendrocytes and increase the number of astrocytes present in vivo.
CD44 labels astrocyte precursors in human fetal tissue
Our results and those of others (Alfei et al., 1999) suggest that CD44 can be used to prospectively identify astrocyte precursors in chick, rat, and mouse. To determine whether a similar strategy can be used to isolate precursors from human fetal cells, we obtained commercially available mixed cultures of neural cells derived from 18-22-week human fetuses, and examined the properties of CD44+ cells. CD44-labeled cells were a population of dividing cells (Figs. 8A,B) and a subset coexpressed astrocyte markers such as S-100h (N90%, Fig. 8D ). At this time, most CD44+ cells were GFAPÀ. However, after growth in human neural precursor cell medium in the presence of 1% fetal bovine serum (ScienCell Research Laboratories) for 10-16 days, virtually all CD44+ cells acquired GFAP expression (Fig.  8E) . Undifferentiated CD44+ cells did not coexpress GRP cell markers such as A2B5 (Fig. 8C) or neuronal markers such as h-III tubulin (Fig. 8F) . No double labeling of CD44+ cells with oligodendrocyte markers Nkx2.2, Olig2, or GalC was observed (data not shown, see also MayerProschel et al., 2002) , suggesting the human CD44+ cells are restricted to the astrocytic lineage. To confirm that this restriction persisted after transplantation, we purified CD44-expressing human cells from human fetal tissue samples obtained from ScienCell Research Laboratories and transplanted them into adult rat spinal cord. As with rodent into rodent transplants, we found that many of the human CD44+ cells, as detected by staining of human specific nuclei (hNUC) in the host spinal cord, expressed , an indicator for mitosis and proliferation. Many of these human cells differentiated into GFAPexpressing astrocytes 2 weeks posttransplantation (Figs. 8DV -FV ), but no cell appeared to have differentiated into neurons or oligodendrocytes as assessed by double labeling with NeuN, h-III tubulin, Nkx2.2, or Olig2 (data not shown).
Discussion
We have shown that astrocytes and astrocyte precursors are present at early developmental ages in the developing brain and can be distinguished from multipotent stem cells and other glial precursors by the expression of CD44, S100h, GLAST, and the absence of markers characteristic of NEP cells (Sox2, Sox1), neuronal lineage (h-III tubulin, PSA-NCAM or E-NCAM, neurofilament, microtubuleassociated protein 2 or MAP2), and GRP cells (A2B5, NG2, PDGFRa, Olig2). CD44 and S-100h double-immunoreactive cells can be readily distinguished from radial glial cells based on their morphology and distribution in vivo and the absence of detectable levels of the radial glial marker RC1 . However, it is difficult to distinguish between these populations in culture as radial glial morphology is significantly altered and RC1 or RC2 expression in vitro cannot be attributed to radial glial cells alone.
We have taken advantage of the availability of antibodies against the extracellular epitope CD44, to isolate the CD44 immunoreactive population from rodent and human tissue, and to assess their properties in vitro and in vivo. Our results show that CD44+ ARP cells harvested from E14.5 and later stages of development are a dividing population of cells that can be maintained in culture over multiple passages and are biased in their differentiation capacity to generate GFAP+ astrocytes in clonal culture and after transplantation into the adult spinal cord. The behavior of ARPs is in contrast to the behavior of GRP cells or NRP cells transplanted under identical conditions, which will readily generate oligodendrocytes and mature neurons (Han et al., , 2004 , suggesting that the bias in differentiation observed is a reflection on the intrinsic potential of the CD44+ precursor cell. Essentially identical results were obtained when human fetal cells were used as a source to harvest CD44+ astrocyte precursors, suggesting that CD44 is a useful marker in chick (Alfei et al., 1999) , rodent, and human tissue. In our clonal analysis of CD44+ cells, we have found that the majority of CD44+ sorted cells only give rise to astrocytes but not cells of other lineages, although we saw occasional differentiation of neuronal or oligodendrocytic lineage. It is therefore unlikely that these cells are multipotent stem cells. However, since plasticity of astrocytes has been reported (Kondo and Raff, 2000) and we have not checked all conditions, we cannot rule out the possibility that some cells may be more developmentally plastic or acquire such plasticity under specific culture conditions (see review Liu and Rao, 2003b) .
The CD44+ ARP cell differs from the cell identified by Mi and Barres (1999) in the immunoreactivity to A2B5 and from the precursor identified by Seidman et al. (1997) in that this is not immortalized. We note that Whittemore et al. have reported that human neural stem cells upon repeated passaging will generate a population of cells that are restricted to differentiating into astrocytes after transplantation (Cao et al., 2001) . While CD44 expression was not demonstrated, the culture conditions, differentiation ability, and absence of GFAP expression suggest that these cells may be similar or identical though definitive proof will require direct comparisons. Horner et al. (2000) have described proliferating cells in the adult rat spinal cord. These cells possess the properties of glial precursors and can give rise to both oligodendrocytes and astrocytes. These cells appear to resemble GRP cells in their expression of Olig genes, Nkx2.2, NG2, and absence of mature markers of oligodendrocytes as well as markers of more primitive stem cells such as Sox1 and Sox2 (Talbott et al., in press ). Whether they differentiate into astrocytes via a CD44+ stage remains to be determined.
Based on the timing and distribution of CD44 expression, we hypothesized that at least a subset of CD44+ ARP cells may arise from the A2B5+/CD44À GRPs, and our results support this idea. A2B5+ cells generate CD44+ cells in mass and clonal cultures (Fig. 3) . The acquisition of CD44 precedes the acquisition of GFAP, and CD44 and GFAP are coexpressed subsequently in culture. Occasional transitional A2B5+/CD44+ cells can be identified in culture, which further suggests a sequential process of differentiation. Equally importantly, A2B5+/CD44À sorted cells can be transplanted in vivo, and these cells differentiate into CD44+ cells, which subsequently acquire GFAP immunoreactivity (Fig. 5) .
Our hypothesis that at least some astrocytes arise via the generation of CD44+ ARPs that are derived from A2B5+ cells is further supported by the data from CNP-CD44 transgenic mice. In this mouse model, the CNP promoter drives specific expression of CD44 in glial progenitors (or GRP cells, Tuohy et al., 2004) . Although the CNP promoter has been shown to be active as early as E12.5 in mice (Chandross et al., 1999) , the increase in CD44 expression likely does not affect embryos until E18 (Tuohy et al., 2004) , when glial precursors choose their fate to enter either into oligodendrocyte lineage or astrocyte lineage. Misexpression of CD44 in this progenitor population results in interference with fate determination and leads to an increase in the number of O4 and GalC immunoreactive cells and a demyelination phenotype (Tuohy et al., 2004) , suggesting a failure for oligodendrocyte precursors to mature beyond the stage of GalC acquisition, a developmental switching point between oligodendrocytic and astrocytic fates (Gregori et al., 2002) . In addition, Fig. 9 . Astrocyte differentiation in the CNS. Neuroepithelial stem cells (NEP), radial glia, and glial-restricted precursor cells (GRP) have all been shown to generate astrocytes. Astrocyte-restricted precursor (ARP), as assessed by CD44 expression, might be one of the intermediate precursors that give rise to mature astrocytes. Note that while radial glia do not normally express CD44, we do not know whether they express CD44 as they mature to become astrocytes. CD44 overexpression prevents glial precursors from differentiating into oligodendrocytes but does not prevent differentiation into astrocytes. this increase in O4 and GalC is accompanied by a dramatic increase in GFAP immunoreactivity and a 10-fold increase in the number of O4+/GFAP+ and GalC+/ GFAP+ cells compared to WT animals ( Fig. 6 ; Tuohy et al., 2004) , indicating that in this CD44 misexpression model, an alteration in cell fate from oligodendrocyte to astrocyte has occurred, which subsequently resulted in the acquisition of astrocyte marker GFAP in oligodendrocyte precursors. Interestingly, similar transition from an oligodendrocyte to astrocyte fate was also observed in other genetically manipulated animal models. In Olig1/2 double-knockout mice Zhou and Anderson, 2002) , an overactivation or loss of fibroblast growth factor receptor 3 (FGFR3) function resulted in alteration of the numbers of both oligodendrocytes and astrocytes (Lin et al., 2003; Oh et al., 2003; Pringle et al., 2003) . While our transgenic mouse data is consistent with our hypothesis, final confirmation will require a direct demonstration in vivo using conditional promoters and Cre-Lox systems that manipulate the A2B5+ GRP cells. Experiments are in progress to generate the appropriate tools.
While the indirect data taken together with the culture and transplant experiments provide strong support for the hypothesis that some astrocytes are derived from CD44+ ARP cells that are derived from GRP cells in vivo, we emphasize, however, that our data (summarized in Fig. 9 ) do not suggest that all astrocytes are derived from a GRP cell. To the contrary, our results are consistent with the idea that more than one lineage of astrocytes are likely present with the GRP-derived astrocyte lineage being a subset of the total number of astrocytes. We do not as yet know which cell(s) contributes to the remaining astrocyte population, though based on the early distribution of GFAP expression , the demonstration of a transition of radial glia to astrocytes (Voigt, 1989) and the maturation of radial glia into astrocytes in vitro (Anton et al., unpublished) all suggest that a subset of astrocytes are derived from radial glia. Whether these astrocytes also go through additional precursor cell stages and whether these precursors express stage-specific markers remain to be determined. Determining the relative contribution of distinct lineages requires developing appropriate assays, markers, and genetically manipulated animals and will be a focus of future experiments.
Overall, our data suggest that, during embryonic development, a subset of astrocytes is generated via a sequential process of differentiation that involves stem cell-GRP-ARP to astrocyte differentiation. Cells at each stage can be distinguished from each other using stagespecific markers while their differentiation ability can be tested in vitro and in vivo upon transplantation. Cell surface epitopes, including CD44, can be used to harvest selected populations of cells. Future experiments will be directed at identifying the lineage relationship, if any, between radial glia and GRP cells, and characterizing properties that distinguish astrocytes derived from distinct developmental lineages.
